|
|
|
| Clinical Efficacy of Leuprolide Acetate Microspheres for Injection Combined with Levonorgestrel Intrauterine Release System in the Treatment of Adenomyosis |
| WEI Hua-li, NIU Xiu-min, WANG Hong-xia |
| Department of Gynecology and obstetrics,Emergency General Hospital,Beijing 100028,China |
|
|
|
|
Abstract 【Objective】To investigate the clinical effects of leuprolide acetate microspheres combined with levonorgestrel intrauterine delivery system in the treatment of adenomyosis (AMS). 【Methods】Seventy-two patients with AMS in our hospital from December 2014 to December 2017 were selected and divided into observation group and control group according to random number table method, 36 cases in each group. The control group was treated with levonorgestrel intrauterine release system, while the observation group was treated with leuprorelin acetate microspheres for injection on the basis of the control group. The curative effect, uterine volume change, menstrual volume change, dysmenorrhea improvement, serum carcinoembryonic antigen (CA125), quality of life score and incidence of adverse reactions were compared between the two groups before and after treatment. 【Results】The total effective rate of the observation group was 94.44%, which was significantly higher than 77.78% of the control group (P<0.05). After 6 months of treatment, the uterine volume of the observation group was significantly smaller than that of the control group, the dysmenorrhea and menstrual volume score and serum CA125 level were significantly lower than those of the control group (P<0.05), and the quality of life score of the observation group was significantly higher than that of the control group (P<0.05). The incidence of adverse reactions in the observation group was 25.00%, and there was no significant difference between the observation group and the control group (19.44%) (P>0.05).【Conclusion】Levonorgestrel intrauterine release system combined with leuprorelin acetate microspheres for injection in the treatment of AMS patients has a significant effect, can significantly improve the clinical symptoms and quality of life of patients, effectively reduce the level of serum CA125, and has high safety, which is worthy of clinical application.
|
|
Received: 12 March 2019
|
|
|
|
|
|
[1] 李巧云,刘秀荣,冯玉珍.亮丙瑞林联合曼月乐治疗子宫腺肌病49例[J].中国药业,2015,24(5):85-86.
[2] 白继红.左炔诺孕酮宫内缓释系统在子宫腺肌病患者治疗中的应用[J].陕西医学杂志,2015,44(2):182-183.
[3] 吴敏,肖琳,柯静珍.醋酸亮丙瑞林微球联合体外受精-胚胎移植治疗子宫腺肌病合并不孕症的疗效观察[J].中国医院用药评价与分析,2016,16(7):905-907.
[4] 谢幸,苟文丽.妇产科学[M].第8版.北京:人民卫生出版社,2013:274.
[5] 孙笑尘.醋酸亮丙瑞林联合曼月乐治疗子宫腺肌症临床效果分析[D].青海大学,2017.
[6] 潘静,王璐,姚丽艳.孕三烯酮不同用药剂量治疗子宫腺肌病的临床对比研究[J].中国妇幼保健,2016,31(14):2824-2826.
[7] 吴建波,黄玉秀,胡继芬.依托孕烯皮下埋植剂治疗子宫腺肌病29例疗效分析[J].中国实用妇科与产科杂志,2018,34(2):209-213.
[8] Devilliers H,Amoura Z,Besancenot JF,et al.Responsiveness of the 36-item short form health survey and the lupus quality of life questionnaire in SLE[J].Rheumatology (Oxford),2015,54(5):940-949.
[9] 石东涛,白睿.桂枝茯苓胶囊联合左炔诺孕酮宫内释放系统治疗子宫腺肌病临床研究[J].海南医学院学报,2016,22(22):2772-2774.
[10] 刘利利,王玫,任景芳,等.注射用醋酸亮丙瑞林微球治疗子宫腺肌病合并不孕60例临床观察[J].医学临床研究,2015,32(1):87-89.
[11] 李欢.CA125和ki67在子宫腺肌病患者中的表达及其临床意义[J].临床和实验医学杂志,2016,15(9):853-856. |
|
|
|
2019, Vol. 36 
